Compare Hims and Hers Health Inc (HIMS) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Marqeta Inc — how do they compare? Hims and Hers Health Inc trades at $28.43 (market cap $6.55B), while Marqeta Inc trades at $17.1 (market cap $1.82B). The key difference: Hims and Hers Health Inc is far larger — about 3.6× Marqeta Inc's market cap, and Marqeta Inc is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Marqeta Inc for 44 Days on average.
| HIMS | MQ | |
|---|---|---|
Market Cap | $6.55B | $1.82B |
Volume | 14,842,814 | 1,126,466 |
Sector | Health | Technology |
52-Week High | $62.76 | $20.32 |
52-Week Low | $14.52 | $15.04 |
Typical Hold Time | 21 Days | 44 Days |
Enterprise Value | $7.25B | $1.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $29.54, up slightly by 0.24% on the day. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators remain neutral. Fundamentally, the company reported revenue of $2.35 billion in 2025 but swung to a net loss of $142 million in 2026, with a negative net margin of 5.51%. Analyst consensus is a 'Hold' with a price target of $32.17, but the stock faces significant headwinds from multiple securities class action lawsuits announced in early October 2026.
The outlook for HIMS is clouded by legal risks and profitability challenges despite revenue growth. Investment opportunity hinges on the company's ability to return to profitability and resolve regulatory scrutiny. Key risks include ongoing litigation, FTC complaints, and execution missteps in a competitive telehealth market. Wall Street remains cautious with 65% of analysts recommending Hold.
MQ trades at $17.06, up 3.08% today, with a bullish technical signal from moving averages. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue is projected to grow to $677 million in 2026, and net income turned positive in 2024 before a slight loss in 2025. Recent partnerships with BVNK for stablecoin-card infrastructure and Google for wallet expansion highlight strategic growth initiatives.
MQ shows improving fundamentals with revenue growth and recent profitability, but high valuation ratios (P/E of 193.83) pose a risk. The consensus price target of $11.38 suggests potential downside, though some analysts see upside to $18.00. Key risks include contract renewals in Q3 2026 and competitive pressures in the fintech sector. The stock's outlook hinges on execution of growth initiatives and sustained earnings improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
